Cargando…

Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology

The efficiency of telestroke programs in improving the rates of recombinant tissue plasminogen activator (rtPA) in stroke patients has been reported. Previous studies have reported favorable treatment outcomes with the use of telestroke programs to improve the use of rtPA, but functional outcomes ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Gainey, Jordan, Brecthtel, Leanne, Blum, Brice, Keels, Aaliyah, Madeline, Lee, Lowther, Ervin, Nathaniel, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144501/
https://www.ncbi.nlm.nih.gov/pubmed/30245570
http://dx.doi.org/10.1177/1179069518793412
_version_ 1783356113455939584
author Gainey, Jordan
Brecthtel, Leanne
Blum, Brice
Keels, Aaliyah
Madeline, Lee
Lowther, Ervin
Nathaniel, Thomas
author_facet Gainey, Jordan
Brecthtel, Leanne
Blum, Brice
Keels, Aaliyah
Madeline, Lee
Lowther, Ervin
Nathaniel, Thomas
author_sort Gainey, Jordan
collection PubMed
description The efficiency of telestroke programs in improving the rates of recombinant tissue plasminogen activator (rtPA) in stroke patients has been reported. Previous studies have reported favorable treatment outcomes with the use of telestroke programs to improve the use of rtPA, but functional outcomes are not fully understood. This study investigated the effect of telestroke technology in the administration of rtPA and related functional outcomes associated with baseline clinical variables. Retrospective data of a telestroke registry were analyzed. Univariate analysis was used to compare demographic and clinical variables in the rtPA group and the no rtPA group and between the improved functional ambulation group and the no improvement group. A stepwise binary logistic regression identified factors associated with improved functional outcome in the total telestroke population and in the subset of the telestroke population who received rtPA. In adjusted analysis and elimination of any multicollinearity for patients who received rtPA in the telestroke setting, obesity (odds ratio [OR] = 2.138, 95% confidence interval [CI], 1.164-3.928, P < .05), higher systolic blood pressure at the time of presentation (OR = 1.015, 95% CI, 1.003-1.027, P < .05), and baseline high-density lipoprotein at the time of admission (OR = 1.032, 95% CI, 1.005-1.059, P < .05) were associated with improved functional outcomes. Increasing age (OR = 0.940, 95% CI, 0.916-0.965, P < .0001) and higher calculated National Institutes of Health Stroke Scale (OR = 0.903, 95% CI, 0.869-0.937) were associated with a poorer outcome in rtPA-treated patients. Telestroke technology improves functional outcomes at spoke stations where neurological expertise is unavailable. Further studies are necessary to determine how telestroke technology can be optimized, especially to improve contraindications and increase eligibility for thrombolysis therapy.
format Online
Article
Text
id pubmed-6144501
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61445012018-09-21 Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology Gainey, Jordan Brecthtel, Leanne Blum, Brice Keels, Aaliyah Madeline, Lee Lowther, Ervin Nathaniel, Thomas J Exp Neurosci Cerebrovascular Disease and Stroke The efficiency of telestroke programs in improving the rates of recombinant tissue plasminogen activator (rtPA) in stroke patients has been reported. Previous studies have reported favorable treatment outcomes with the use of telestroke programs to improve the use of rtPA, but functional outcomes are not fully understood. This study investigated the effect of telestroke technology in the administration of rtPA and related functional outcomes associated with baseline clinical variables. Retrospective data of a telestroke registry were analyzed. Univariate analysis was used to compare demographic and clinical variables in the rtPA group and the no rtPA group and between the improved functional ambulation group and the no improvement group. A stepwise binary logistic regression identified factors associated with improved functional outcome in the total telestroke population and in the subset of the telestroke population who received rtPA. In adjusted analysis and elimination of any multicollinearity for patients who received rtPA in the telestroke setting, obesity (odds ratio [OR] = 2.138, 95% confidence interval [CI], 1.164-3.928, P < .05), higher systolic blood pressure at the time of presentation (OR = 1.015, 95% CI, 1.003-1.027, P < .05), and baseline high-density lipoprotein at the time of admission (OR = 1.032, 95% CI, 1.005-1.059, P < .05) were associated with improved functional outcomes. Increasing age (OR = 0.940, 95% CI, 0.916-0.965, P < .0001) and higher calculated National Institutes of Health Stroke Scale (OR = 0.903, 95% CI, 0.869-0.937) were associated with a poorer outcome in rtPA-treated patients. Telestroke technology improves functional outcomes at spoke stations where neurological expertise is unavailable. Further studies are necessary to determine how telestroke technology can be optimized, especially to improve contraindications and increase eligibility for thrombolysis therapy. SAGE Publications 2018-09-18 /pmc/articles/PMC6144501/ /pubmed/30245570 http://dx.doi.org/10.1177/1179069518793412 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Cerebrovascular Disease and Stroke
Gainey, Jordan
Brecthtel, Leanne
Blum, Brice
Keels, Aaliyah
Madeline, Lee
Lowther, Ervin
Nathaniel, Thomas
Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology
title Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology
title_full Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology
title_fullStr Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology
title_full_unstemmed Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology
title_short Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology
title_sort functional outcome measures of recombinant tissue plasminogen activator–treated stroke patients in the telestroke technology
topic Cerebrovascular Disease and Stroke
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144501/
https://www.ncbi.nlm.nih.gov/pubmed/30245570
http://dx.doi.org/10.1177/1179069518793412
work_keys_str_mv AT gaineyjordan functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology
AT brecthtelleanne functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology
AT blumbrice functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology
AT keelsaaliyah functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology
AT madelinelee functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology
AT lowtherervin functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology
AT nathanielthomas functionaloutcomemeasuresofrecombinanttissueplasminogenactivatortreatedstrokepatientsinthetelestroketechnology